New dosing study aims to protect kids from latent TB
NCT ID NCT03730181
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This study looked at how to best dose two medicines, rifapentine and isoniazid, for children aged 0-12 with latent (hidden) tuberculosis infection. The goal was to find a dose that works as well as in adults to prevent the infection from turning into active TB. The study included both HIV-infected and HIV-uninfected children to ensure safety and effectiveness for all.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LATENT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Desmond Tutu TB Center, University of Stellenbosch
Stellenbosch, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a once-weekly TB pill safely mix with HIV treatment in kids?
- Common TB drug may fuel superbug resistance, study warns
- Blood test aims to unmask hidden TB infections before they turn deadly
- Cash and cameras: a new way to beat latent TB?
- TB prevention breakthrough? 6-Week regimen could replace months of treatment
- Can a 2-Month TB prevention be as good as 4 months?